Search Results

Your search for Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD,Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD matches 2 pages

Showing 1 - 2

By Matthew Stenger / August 15 2012

No Improvement in Overall Survival, Worse Toxicity with Motesanib Added to Chemotherapy in Non–Small Cell Lung Cancer

Two trials (E4599 and AVAiL) have suggested a benefit to adding the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) to chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Bevacizumab acts by binding directly to circulating...

lung cancer

By Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD / January 15, 2014

Adjuvant Gefitinib in Patients With NSCLC: Bad Idea or Wrong Patient Selection?

Despite optimal surgical resection and adjuvant chemotherapy with cisplatin-based doublets, the 5-year overall survival for patients with early-stage non–small cell lung cancer (NSCLC) remains suboptimal. In the International Association for the Study of Lung Cancer (IASLC) staging project, the...

Apr

Today In Oncology

Search Results

Your search for Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD,Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD matches 2 pages

No Improvement in Overall Survival, Worse Toxicity with Motesanib Added to Chemotherapy in Non–Small Cell Lung Cancer

Adjuvant Gefitinib in Patients With NSCLC: Bad Idea or Wrong Patient Selection?

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma